@article{8d13e59efa714e9f8754fe9fba83853e,
title = "Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100",
abstract = "Administration of BAS 100, a novel mechanism-based CYP3A4 inhibitor isolated from grapefruit juice, resulted in a 2.1-fold increase in erlotinib exposure following oral administration to wild-type and humanised CYP3A4 transgenic mice. This study illustrates the potential of BAS 100 to increase the low and variable oral bioavailability of erlotinib in cancer patients.",
keywords = "CYP3A4 transgenic, Grapefruit, Metabolism, OSI-420, OSI-774, Tarceva",
author = "Smith, {N. F.} and Baker, {S. D.} and Gonzalez, {F. J.} and Harris, {J. W.} and Figg, {W. D.} and A. Sparreboom",
note = "Funding Information: This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (Bethesda, MD, USA). We thank Dr Linda G Byrd (Laboratory of Metabolism, Centre for Cancer Research, National Cancer Institute, Bethesda, MD, USA) for assistance with the CYP3A4 transgenic mouse study and Dr Ming Zhao (Johns Hopkins",
year = "2008",
month = may,
day = "20",
doi = "10.1038/sj.bjc.6604353",
language = "English",
volume = "98",
pages = "1630--1632",
journal = "British Journal of Cancer",
issn = "0007-0920",
number = "10",
}